Search research articles
Contact Us
Filters
Showing results (241-250 of 252) with videos related to
Page
of 26
Sort By:
Nature Microbiology
|
October 20, 2022
CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery
H J Benns, M Storch, J A Falco, et al.
Hematological Oncology
|
October 12, 2000
Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests
F E Davies, A C Rawstron, G Pratt, et al.
Leukemia
|
August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
K D Boyd, F M Ross, L Chiecchio, et al.
Cancer Research
|
November 1, 1982
Use of hair dyes and risk of bladder cancer
P Hartge, R Hoover, R Altman, et al.
Lancet (London, England)
|
July 31, 2007
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D Catovsky, S Richards, E Matutes, et al.
Journal of Medical Genetics
|
March 4, 2008
Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands
L Faivre, G Collod-Beroud, A Child, et al.
American Journal of Medical Genetics. Part A
|
April 9, 2009
Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion
L Faivre, G Collod-Beroud, B Callewaert, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 22, 2022
Malaria parasite evades mosquito immunity by glutaminyl cyclase-mediated posttranslational protein modification
Surendra Kumar Kolli, Alvaro Molina-Cruz, Tamasa Araki, et al.
European Journal of Human Genetics : EJHG
|
November 13, 2008
Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation
L Faivre, G Collod-Beroud, B Callewaert, et al.
Clinical Genetics
|
May 14, 2011
The new Ghent criteria for Marfan syndrome: what do they change?
L Faivre, G Collod-Beroud, L Adès, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 252) with videos related to
Sort By:
Page
of 26
Nature Microbiology
|
October 20, 2022
CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery
H J Benns, M Storch, J A Falco, et al.
Hematological Oncology
|
October 12, 2000
Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests
F E Davies, A C Rawstron, G Pratt, et al.
Leukemia
|
August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
K D Boyd, F M Ross, L Chiecchio, et al.
Cancer Research
|
November 1, 1982
Use of hair dyes and risk of bladder cancer
P Hartge, R Hoover, R Altman, et al.
Lancet (London, England)
|
July 31, 2007
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D Catovsky, S Richards, E Matutes, et al.
Journal of Medical Genetics
|
March 4, 2008
Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands
L Faivre, G Collod-Beroud, A Child, et al.
American Journal of Medical Genetics. Part A
|
April 9, 2009
Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion
L Faivre, G Collod-Beroud, B Callewaert, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 22, 2022
Malaria parasite evades mosquito immunity by glutaminyl cyclase-mediated posttranslational protein modification
Surendra Kumar Kolli, Alvaro Molina-Cruz, Tamasa Araki, et al.
European Journal of Human Genetics : EJHG
|
November 13, 2008
Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation
L Faivre, G Collod-Beroud, B Callewaert, et al.
Clinical Genetics
|
May 14, 2011
The new Ghent criteria for Marfan syndrome: what do they change?
L Faivre, G Collod-Beroud, L Adès, et al.
Page
of 26